Central Nervous System Disease in Patients With RETFusion-Positive NSCLC Treated With Selpercatinib

Central nervous system (CNS) metastases develop in nearly half of patients and cause morbidity and mortality in RETfusion-positive NSCLCs. The selective RET inhibitor selpercatinib treats existing intracranial disease, but no studies have investigated whether early initiation of selpercatinib is associated with decreased development of CNS metastases.